Education
About Us
Working with TipRanks
Follow Us
Pacira Pharmaceuticals (PCRX)
NASDAQ:PCRX
PCRX Stock Chart & Stats
$20.65
-$0.08(-0.43%)
At close: 4:00 PM EST
$20.65
-$0.08(-0.43%)
Day’s Range― - ―
52-Week Range$19.84 - $27.64
Previous CloseN/A
Volume54.84K
Average Volume (3M)846.49K
Market Cap
$956.79M
Enterprise ValueN/A
Total Cash (Recent Filing)$246.33M
Total Debt (Recent Filing)$425.31M
Price to Earnings (P/E)46.3
Beta0.85
Next Earnings
Feb 19, 2026EPS Estimate
0.91Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.70
Shares Outstanding43,021,275
10 Day Avg. Volume930,153
30 Day Avg. Volume846,493
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)1.12
Price to Sales (P/S)1.24
P/FCF Ratio4.87
Enterprise Value/Market Cap0.00
Enterprise Value/Revenue0.00
Enterprise Value/Gross Profit0.00
Enterprise Value/Ebitda0.00
Forecast
1Y Price Target
$29.71Price Target Upside43.87% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering7
EPS Forecast (FY)3.41
Revenue Forecast (FY)$797.47M
Bulls Say, Bears Say
Bulls Say
Clinical Adoption And ReimbursementSteady Exparel adoption supported by favorable clinical evidence and reimbursement dynamics increases the likelihood of broader use in surgical pain management and revenue renewal.
Pipeline Clinical PotentialPromising clinical data for the IL-1Ra gene therapy candidate in osteoarthritis could evolve into a high-value pipeline asset that diversifies revenue beyond the core product.
Share RepurchaseCompletion of a sizable share repurchase and remaining buyback capacity supports shareholder value by reducing outstanding shares and improving per-share metrics.
Bears Say
Generic Competition RiskNotification of an ANDA filing from an experienced generics manufacturer raises the prospect of generic Exparel entrants that could materially erode market share and sales.
Patent Litigation UncertaintyInvalidity rulings and prolonged appeals create legal uncertainty around key Exparel patents, potentially threatening long-term exclusivity and valuation.
Revenue Performance And Growth SlowdownRevenue slightly below consensus and a decelerating pace of Exparel volume growth can weaken investor sentiment and limit near-term upside for the stock.
Pacira Pharmaceuticals News
PCRX FAQ
What was Pacira Pharmaceuticals’s price range in the past 12 months?
Pacira Pharmaceuticals lowest stock price was $19.84 and its highest was $27.64 in the past 12 months.
What is Pacira Pharmaceuticals’s market cap?
Pacira Pharmaceuticals’s market cap is $956.79M.
When is Pacira Pharmaceuticals’s upcoming earnings report date?
Pacira Pharmaceuticals’s upcoming earnings report date is Feb 19, 2026 which is in 33 days.
How were Pacira Pharmaceuticals’s earnings last quarter?
Pacira Pharmaceuticals released its earnings results on Nov 06, 2025. The company reported $0.7 earnings per share for the quarter, beating the consensus estimate of $0.677 by $0.023.
Is Pacira Pharmaceuticals overvalued?
According to Wall Street analysts Pacira Pharmaceuticals’s price is currently Undervalued.
Does Pacira Pharmaceuticals pay dividends?
Pacira Pharmaceuticals does not currently pay dividends.
What is Pacira Pharmaceuticals’s EPS estimate?
Pacira Pharmaceuticals’s EPS estimate is 0.91.
How many shares outstanding does Pacira Pharmaceuticals have?
Pacira Pharmaceuticals has 43,021,275 shares outstanding.
What happened to Pacira Pharmaceuticals’s price movement after its last earnings report?
Pacira Pharmaceuticals reported an EPS of $0.7 in its last earnings report, beating expectations of $0.677. Following the earnings report the stock price went up 4.502%.
Which hedge fund is a major shareholder of Pacira Pharmaceuticals?
Currently, no hedge funds are holding shares in PCRX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Pacira Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$29.71 (43.87% Upside)
$29.71 (43.87% Upside)
Blogger Sentiment
Bullish
PCRX Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 105.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 3.6%
Last 30 Days ▲ 16.5%
Last 30 Days ▲ 16.5%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-5.62%
12-Months-Change
Fundamentals
Return on Equity
2.90%
Trailing 12-Months
Asset Growth
-14.73%
Trailing 12-Months
Company Description
Pacira Pharmaceuticals
Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for healthcare practitioners and their patients in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature only to targeted nerves. It also develops proprietary multivesicular liposome, a drug delivery technology that encapsulates drugs without altering their molecular structure. The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019. Pacira BioSciences, Inc. was incorporated in 2006 and is headquartered in Tampa, Florida.
PCRX Company Deck
PCRX Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted strong revenue growth, improved manufacturing efficiencies, and significant pipeline expansion. However, some challenges were noted with Zilretta's slower-than-expected sales growth and discount impacts from new GPO agreements affecting pricing. Elective procedure market growth was also described as sluggish.View all PCRX earnings summariesPCRX Stock 12 Month Forecast
Average Price Target
$29.71
▲(43.87% Upside)
Technical Analysis
Avadel Pharmaceuticals
―
Supernus Pharmaceuticals
―
ANI Pharmaceuticals
―
Amphastar Pharmaceuticals
―
Collegium Pharmaceutical
―
Ownership Overview
2.82% Insiders
24.96% Mutual Funds
22.96% Other Institutional Investors
16.17% Public Companies and
Individual Investors